|
1
|
Cancer Research UK: Leukaemia (all
subtypes combined) statistics. Cancer Research UK; Oxford: 2016,
https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia.
|
|
2
|
Lun Y, Yang JJ and Wu Y: Complete
molecular remission in relapsed and refractory acute myeloid
leukaemia with MLL-AF9 treated with chidamide-based chemotherapy. J
Clin Pharm Ther. 42:786–789. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Daigle SR, Olhava EJ, Therkelsen CA, Majer
CR, Sneeringers CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao
Y, et al: Selective killing of mixed lineage leukemia cells by a
potent small-molecule DOT1L inhibitor. Cancer Cell. 20:53–65. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hassan C, Afshinnekoo E, Li S, Wu S and
Mason CE: Genetic and epigenetic heterogeneity and the impact on
cancer relapse. Exp Hematol. 54:26–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Madanat YF, Kalaycio ME and Nazha A:
Advances in acute myeloid leukemia genomics, where do we stand in
2018? Acta Med Acad. 48:35–44. 2019.PubMed/NCBI
|
|
6
|
Ding L, Ley TJ, Larson DE, Miller CA,
Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan
MD, et al: Clonal evolution in relapsed acute myeloid leukaemia
revealed by whole-genome sequencing. Nature. 481:506–510. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zahreddine H and Borden KLB: Mechanisms
and insights into drug resistance in cancer. Front Pharmacol.
4:282013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu X and Xuan Y: Bypassing cancer drug
resistance by activating multiple death pathways - a proposal from
the study of circumventing cancer drug resistance by induction of
necroptosis. Cancer Lett. 259:127–137. 2008. View Article : Google Scholar
|
|
9
|
Nikoletopoulou V, Markaki M, Palikaras K
and Tavernarakis N: Crosstalk between apoptosis, necrosis and
autophagy. Biochim Biophys Acta. 1833:3448–3459. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT,
Liu B and Bao JK: Programmed cell death pathways in cancer: A
review of apoptosis, autophagy and programmed necrosis. Cell
Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Radogna F, Dicato M and Diederich M:
Cancer-type-specific crosstalk between autophagy, necroptosis and
apoptosis as a pharmacological target. Biochem Pharmacol. 94:1–11.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goodall ML, Fitzwalter BE, Zahedi S, Wu M,
Rodriguez D, Mulcahy-Levy JM, Green DR, Morgan M, Cramer SD and
Thorburn A: The autophagy machinery controls cell death switching
between apoptosis and necroptosis. Dev Cell. 37:337–349. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liang J, Shao SH, Xu ZX, Hennessy B, Ding
Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, et al:
The energy sensing LKB1-AMPK pathway regulates p27(kip1)
phosphorylation mediating the decision to enter autophagy or
apoptosis. Nat Cell Biol. 9:218–224. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ding WX, Ni HM, Gao W, Hou YF, Melan MA,
Chen X, Stolz DB, Shao ZM and Yin XM: Differential effects of
endoplasmic reticulum stress-induced autophagy on cell survival. J
Biol Chem. 282:4702–4710. 2007. View Article : Google Scholar
|
|
15
|
Decuypere JP, Parys JB and Bultynck G:
Regulation of the autophagic bcl-2/beclin 1 interaction. Cells.
1:284–312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marquez RT and Xu L: Bcl-2:Beclin 1
complex: multiple, mechanisms regulating autophagy/apoptosis toggle
switch. Am J Cancer Res. 2:214–221. 2012.PubMed/NCBI
|
|
17
|
Lian J, Karnak D and Xu L: The
Bcl-2-Beclin 1 interaction in (-)-gossypol-induced autophagy versus
apoptosis in prostate cancer cells. Autophagy. 6:1201–1203. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Usmani S, Sivagnanalingam U, Tkachenko O,
Nunez L, Shand JC and Mullen CA: Support of acute lymphoblastic
leukemia cells by nonmalignant bone marrow stromal cells. Oncol
Lett. 17:5039–5049. 2019.PubMed/NCBI
|
|
19
|
Matsuo Y, MacLeod RA, Uphoff CC, Drexler
HG, Nishizaki C, Katayama Y, Kimura G, Fujii N, Omoto E, Harada M,
et al: Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13
and MOLM-14) with interclonal phenotypic heterogeneity showing
MLL-AF9 fusion resulting from an occult chromosome insertion,
ins(11;9)(q23;p22p23). Leukemia. 11:1469–1477. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gomez-Bougie P, Maïga S, Tessoulin B,
Bourcier J, Bonnet A, Rodriguez MS, Le Gouill S, Touzeau C, Moreau
P, Pellat-Deceunynck C, et al: BH3-mimetic toolkit guides the
respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
Blood. 132:2656–2669. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Campos EdV: Pinto R: Targeted therapy with
a selective BCL-2 inhibitor in older patients with acute myeloid
leukemia. Hematology Transfus Cell Ther. 41:169–177. 2019.
View Article : Google Scholar
|
|
22
|
McHowat J, Swift LM, Arutunyan A and
Sarvazyan N: Clinical concentrations of doxorubicin inhibit
activity of myocardial membrane-associated, calcium-independent
phospholipase A(2). Cancer Res. 61:4024–4029. 2001.PubMed/NCBI
|
|
23
|
Rudolfová P, Hanušová V, Skálová L,
Bártíková H, Matoušková P and Boušová I: Effect of selected
catechins on doxorubicin anti-proliferative efficacy and
hepatotoxicity in vitro. Acta Pharm. 64:199–209. 2014. View Article : Google Scholar
|
|
24
|
Fornari FA, Randolph JK, Yalowich JC,
Ritke MK and Gewirtz DA: Interference by doxorubicin with DNA
unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 45:649–656.
1994.PubMed/NCBI
|
|
25
|
Inoue-Yamauchi A, Jeng PS, Kim K, Chen HC,
Han S, Ganesan YT, Ishizawa K, Jebiwott S, Dong Y, Pietanza MC, et
al: Targeting the differential addiction to anti-apoptotic BCL-2
family for cancer therapy. Nat Commun. 8:160782017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Florou D, Patsis C, Ardavanis A and
Scorilas A: Effect of doxorubicin, oxaliplatin, and methotrexate
administration on the transcriptional activity of BCL-2 family gene
members in stomach cancer cells. Cancer Biol Ther. 14:587–596.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Panaretakis T, Pokrovskaja K, Shoshan MC
and Grandér D: Activation of Bak, Bax, and BH3-only proteins in the
apoptotic response to doxorubicin. J Biol Chem. 277:44317–44326.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gamen S, Anel A, Pérez-Galán P, Lasierra
P, Johnson D, Piñeiro A and Naval J: Doxorubicin treatment
activates a Z-VAD-sensitive caspase, which causes deltapsim loss,
caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res.
258:223–235. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Moon JH, Sohn SK, Lee MH, Jang JH, Kim K,
Jung CW and Kim DH: BCL2 gene polymorphism could predict the
treatment outcomes in acute myeloid leukemia patients. Leuk Res.
34:166–172. 2010. View Article : Google Scholar
|
|
30
|
Bien S, Rimmbach C, Neumann H, Niessen J,
Reimer E, Ritter CA, Rosskopf D, Cinatl J, Michaelis M, Schroeder
HW, et al: Doxorubicin-induced cell death requires cathepsin B in
HeLa cells. Biochem Pharmacol. 80:1466–1477. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pilco-Ferreto N and Calaf GM: Influence of
doxorubicin on apoptosis and oxidative stress in breast cancer cell
lines. Int J Oncol. 49:753–762. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Akgul C, Moulding DA and Edwards SW:
Alternative splicing of Bcl-2-related genes: Functional
consequences and potential therapeutic applications. Cell Mol Life
Sci. 61:2189–2199. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guillem V, Amat P, Collado M, Cervantes F,
Alvarez-Larrán A, Martínez J, Tormo E, Eroles P, Solano C and
Hernández-Boluda JC: BCL2 gene polymorphisms and splicing variants
in chronic myeloid leukemia. Leuk Res. 39:1278–1284. 2015.
View Article : Google Scholar
|
|
34
|
Tanaka S, Saito K and Reed JC:
Structure-function analysis of the Bcl-2 oncoprotein. Addition of a
heterologous transmembrane domain to portions of the Bcl-2 beta
protein restores function as a regulator of cell survival. J Biol
Chem. 268:10920–10926. 1993.PubMed/NCBI
|
|
35
|
Ghassemifar R, Forster L, Finlayson J,
Calogero T, Augustson B, Joske D and Cull G: Differential
expression of the Bcl-2 and Bax isoforms in CD19 positive
B-lymphocytes isolated from patients diagnosed with chronic
lymphocytic leukaemia. Pathology. 44:632–637. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Manetto V, Lorenzini R, Cordon-Cardo C,
Krajewski S, Rosai J, Reed JC and Eusebi V: Bcl-2 and Bax
expression in thyroid tumours. An immunohistochemical and western
blot analysis. Virchows Arch. 430:125–130. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang JM, Lin TY, Chang D, Lin SL and Ying
SY: Truncated Bcl-2, a potential pre-metastatic marker in prostate
cancer. Biochem Biophys Res Commun. 306:912–917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Messingerova L, Imrichova D, Kavcova H,
Turakova K, Breier A and Sulova Z: Acute myeloid leukemia cells
MOLM-13 and SKM-1 established for resistance by azacytidine are
crossresistant to P-glycoprotein substrates. Toxicol In Vitro.
29:1405–1415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Daniel F, Legrand A, Pessayre D, Vadrot N,
Descatoire V and Bernuau D: Partial Beclin 1 silencing aggravates
doxorubicin- and Fas-induced apoptosis in HepG2 cells. World J
Gastroenterol. 12:2895–2900. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pan Y, Gao Y, Chen L, Gao G, Dong H, Yang
Y, Dong B and Chen X: Targeting autophagy augments in vitro and in
vivo anti-myeloma activity of DNA-damaging chemotherapy. Clin
Cancer Res. 17:3248–3258. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pattingre S, Tassa A, Qu X, Garuti R,
Liang XH, Mizushima N, Packer M, Schneider MD and Levine B: Bcl-2
antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell.
122:927–939. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Boya P, González-Polo RA, Casares N,
Perfettini JL, Dessen P, Larochette N, Métivier D, Meley D,
Souquere S, Yoshimori T, et al: Inhibition of macroautophagy
triggers apoptosis. Mol Cell Biol. 25:1025–1040. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Smuder AJ, Kavazis AN, Min K and Powers
SK: Exercise protects against doxorubicin-induced markers of
autophagy signaling in skeletal muscle. J Appl Physiol (1985).
111:1190–1198. 2011. View Article : Google Scholar
|
